# Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

> **NCT01520116** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Altheos, Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Stage 1 - ATS907 - Dose 1
- **DRUG:** Stage 1 - ATS907 - Dose 2
- **DRUG:** Stage 1 - ATS907 - Dose 3
- **DRUG:** Stage 1 - ATS907 - Dose 4
- **DRUG:** Stage 1 - Vehicle
- **DRUG:** Stage 2 - ATS907 - Dose A - to be selected based on Stage 1
- **DRUG:** Stage 2 - ATS907 - Dose B - to be selected based on Stage 1
- **DRUG:** Timoptic

## Key facts

- **NCT ID:** NCT01520116
- **Lead sponsor:** Altheos, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2012-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520116, "Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01520116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*